GlassScriptPhysician profile
Nora C Hurt
NPI 1437180502
$7,971.03
in general payments reported to CMS, 2019-2025
39 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $402 · 2021: $145 · 2022: $758 · 2023: $1,194 · 2024: $2,342 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,488.02 |
| Education | $298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,220.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,133.11 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.83 | 2019-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $596.28 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $588.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Inspire Medical Systems, INC. | $418.14 | 2022-2025 | Inspire |
| Grifols USA, LLC | $373.73 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $303.17 | 2019-2024 | |
| Insmed, INC. | $289.04 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $268.47 | 2020-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $235.22 | 2023-2025 | Winrevair |
| Axsome Therapeutics, INC. | $187.31 | 2023-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $182.48 | 2021-2025 | Acthar |
| Amgen INC. | $163.50 | 2022-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $152.37 | 2023-2025 | Purified Cortrophin Gel |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $141.43 | 2022-2025 | Glassia |
| Mylan Specialty L.P. | $114.36 | 2019-2023 | Yupelri |
| United Therapeutics Corporation | $107.35 | 2023-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Csl Behring | $92.99 | 2023-2024 | Hizentra |
| Baxter Healthcare | $76.64 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $74.14 | 2024-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $67.64 | 2025 | Ohtuvayre |
| Resmed Corp | $67.49 | 2023-2025 | |
| Viatris Specialty LLC | $67.12 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $59.16 | 2019 | |
| La Jolla Pharmaceutical Company | $49.72 | 2023-2024 | Giapreza |
| 3b Medical, INC. | $42.88 | 2025 | Luna |
| Sunovion Pharmaceuticals INC. | $21.66 | 2019 | |
| Tactile Systems Technology INC | $19.28 | 2024 | Entre Plus, Flexitouch Plus |
| Eisai INC. | $19.17 | 2020 | |
| Lilly USA, LLC | $18.37 | 2025 | Zepbound |
| Genentech USA, INC. | $18.10 | 2019 | |
| Covis Pharma Gmbh | $18.00 | 2023 | |
| Allergan, INC. | $17.75 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.25 | 2022 | |
| Electromed, INC. | $14.11 | 2023 | Smartvest |
| Janssen Pharmaceuticals, INC | $11.18 | 2019 | |
| Inogen, INC. | $9.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Hurt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.